ClinicalTrials.gg
RecruitingNCT06752928Updated Oct 8, 2025

A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes

An interventional study of Dexcom G7 rtCGM and Capillary Blood glucose Testing (POC) in Type 1 Diabetes, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Diabetes Mellitus, Type 1 by Emory University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Emory University.

Planned enrollment
3rd of 13
100 · median 24
Started
2025
with 2 others
No phase
5 of 14
4 open now
Registered
12th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 1 by Emory University, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

5 of the 14 studies in Diabetes Mellitus, Type 1 by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 1 by Emory University, or all of them as a file.
02

Study summary

This study aims to compare inpatient glycemic control by measuring the percentage of time in the range of 70-180 mg/dl and the frequency of hypoglycemia between Dexcom G7 Continuous Glucose Monitoring (CGM) and Point of Care (POC) Blood Glucose Testing in poorly controlled subjects with Type 1 Diabetes Mellitus.

The main question it aims to answer is:

-Whether there is a difference between POC testing (standard of care) and Real-time CGM in glycemic control and hypoglycemic events during hospitalization:

Read the detailed description

The CDC reports that 1.6 million U.S. adults (5.7%) have type 1 diabetes (T1D), with hospitalization rates three times higher than the general population, primarily due to diabetes-related complications such as ketoacidosis and cardiovascular disease. A study at Emory University found that hospitalized T1D patients are younger, experience longer stays and more admissions, and face worse glycemic control and higher rates of hypoglycemia compared to type 2 diabetes (T2D) patients.

Point-of-care (POC) capillary glucose testing is the standard for monitoring hospitalized diabetes patients, but continuous glucose monitoring (CGM) offers more detailed glycemic profiles. Research, including trials using Dexcom CGM systems, has demonstrated CGM's superior ability to detect hypo- and hyperglycemia, reduce hypoglycemic events, and improve insulin therapy adjustments in T2D patients. However, no randomized controlled studies have evaluated the best glucose monitoring system for hospitalized T1D patients.

The proposed study aims to compare POC testing with Dexcom G7 CGM for guiding insulin therapy in hospitalized T1D patients. Researchers hypothesize that CGM will better prevent hypoglycemia and improve glycemic management during hospital stays, addressing a critical gap in evidence regarding glucose control's impact on T1D hospital outcomes.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Continuous Glucose Monitoring
  • Type 1 Diabetes Mellitus
  • Point of Care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro]), intermediate-acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations.
  • Admission diagnosis of T1D with poorly controlled diabetes (blood glucose > 180 mg/dl, > 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
  • Expected length of hospital stay > three days at the time of randomization

Exclusion criteria

Exclusion Criteria:

  • Patients admitted to the ICU
  • Subjects using CGM technology before admission
  • Subjects with type 2 diabetes
  • Treatment with systemic agents
  • Cystic fibrosis
  • Prisoners
  • Patients expected to require MRI procedures during hospitalization.
  • Female subjects who are pregnant or breastfeeding at enrollment into the study.
  • Subjects not willing to wear a CGM device
  • Subjects with hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (\< 30 ml/min), or terminal illness.
  • Subjects with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Standard of Care

    Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) with intravenous or subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded to the electronic medical record (EMR) system. The research team, together with the Primary care (PCP) team, will adjust daily insulin orders based on POC readings (standard of care). In addition, subjects will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, medicine, or research teams) during hospitalization for up to 10 days.

    Diagnostic Test: Capillary Blood glucose Testing (POC)

  • Experimental
    Dexcom CGM

    Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) intravenously with subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Subjects will wear a real-time Dexcom G7 CGM for up to 10 days. Insulin therapy will be titrated based on daily CGM reports, including mean glucose, glycemic excursions, hypoglycemia, and severe hyperglycemia \> 180 and \>250 mg/dl values. Participants will wear a Dexcom rtCGM for up to 10 days during hospitalization.

    Device: Dexcom G7 rtCGM

Interventions

  • DeviceDexcom G7 rtCGM

    The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 CGM System or G7) is a glucose monitoring system that continuously measures glucose in the interstitial fluid. It aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments

  • Diagnostic testCapillary Blood glucose Testing (POC)

    POC glucose meters measure whole blood and convert the results to plasma glucose concentrations, which is the standardized form used in clinical practice.

    Also known as: POCT (point of care therapy)

06

What researchers measure

Primary outcomes

  1. Glycemic control

    The total difference in blood sugar levels between the POC testing (standard of care) group and the rtCGM group throughout the hospitalization

    Time frame: Through study completion (Day 10 or the length of admission)

  2. Clinically significant hypoglycemia <54 mg/dl

    The difference between blood sugar levels in POC testing (standard of care) group and rtCGM group during hospitalization

    Time frame: Through study completion (Day 10 or the length of admission)

Secondary outcomes

  1. Time above range

    % time above Target Above range (TAR). Differences between the both groups will be calculated. (TAR, \>250 mg/dl)

    Time frame: Through study completion (Day 10 or the length of admission)

  2. Time below range

    % time in Below Target range (TBR). Differences between the both groups will be calculated. Differences between the both groups will be calculated. (TBR, \< 70 and 54 mg/dl)

    Time frame: Through study completion (Day 10 or the length of admission)

  3. Glycemic Variability [% Coefficient of Variation (%CV)

    % coefficient of variation will be measured during the intervention phase, compared to control, as measured by CGM.

    Time frame: Through study completion (Day 10 or the length of admission)

  4. Hypoglycemic events

    Number of hypoglycemia events \< 70 and 54 mg/dl

    Time frame: Through study completion (Day 10 or the length of admission)

  5. Hyperglycemic events

    Number of hypoglycemia events \>250 mg/dl

    Time frame: Through study completion (Day 10 or the length of admission)

  6. Nocturnal hypoglycemia

    Number of hypoglycemic events (\<70 and \<54 mg/dl) between 22:00 and 06:00

    Time frame: Through study completion (Day 10 or the length of admission)

  7. Prolonged hypoglycemia

    Number of events of Prolonged hypoglycemia \< 70 mg/dl for more than 2 hours by CGM

    Time frame: Through study completion (Day 10 or the length of admission)

  8. Hospital Complications

    Hospital complications include a composite of acute kidney injury (doubling of serum creatinine \>0.5 mg/dl from baseline), cardiovascular events, infections, and death

    Time frame: Through study completion (Day 10 or the length of admission)

  9. Recurrent hypoglycemia

    Number of recurrent hypoglycemic episodes (\< 70 mg/dl)

    Time frame: Through study completion (Day 10 or the length of admission)

  10. Recurrent hyperglycemia

    Number of recurrent hyperglycemic episodes (\>250 mg/dl)

    Time frame: Through study completion (Day 10 or the length of admission)

Other outcomes

  1. Clinically significant hypoglycemia

    Number of clinically significant hypoglycemic episodes: \<54 mg/dl

    Time frame: Through study completion (Day 10 or the length of admission)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 17 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 31, 2024
StartActual
May 12, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752928
Lead sponsor
Emory University
Collaborators
DexCom, Inc.
Responsible party
Guillermo Umpierrez (Professor, Emory University) — Principal investigator
First posted
Dec 31, 2024
Start date
May 12, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Oct 8, 2025

Study contacts

Guillermo Umpierrez, MD
Contact
geumpie@emory.edu
404-778-1665
Guillermo Umpierrez, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion